WallStSmart

Astrana Health Inc (ASTH)vsTenet Healthcare Corporation (THC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tenet Healthcare Corporation generates 467% more annual revenue ($21.81B vs $3.84B). THC leads profitability with a 10.3% profit margin vs 1.1%. THC trades at a lower P/E of 10.0x. THC earns a higher WallStSmart Score of 74/100 (B).

ASTH

Buy

56

out of 100

Grade: C

Growth: 10.0Profit: 4.5Value: 4.7Quality: 4.5
Piotroski: 1/9Altman Z: 2.10

THC

Strong Buy

74

out of 100

Grade: B

Growth: 6.7Profit: 8.0Value: 6.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.73

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ASTH3 strengths · Avg: 9.3/10
Revenue GrowthGrowth
48.5%10/10

Revenue surging 48.5% year-over-year

EPS GrowthGrowth
110.5%10/10

Earnings expanding 110.5% YoY

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

THC3 strengths · Avg: 10.0/10
P/E RatioValuation
10.0x10/10

Attractively priced relative to earnings

Return on EquityProfitability
48.1%10/10

Every $100 of equity generates 48 in profit

EPS GrowthGrowth
213.4%10/10

Earnings expanding 213.4% YoY

Areas to Watch

ASTH4 concerns · Avg: 3.0/10
Market CapQuality
$1.89B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
3.8%3/10

ROE of 3.8% — below average capital efficiency

Profit MarginProfitability
1.1%3/10

1.1% margin — thin

Operating MarginProfitability
3.5%3/10

Operating margin of 3.5%

THC3 concerns · Avg: 3.0/10
PEG RatioValuation
1.844/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.734/10

Distress zone — elevated risk

Debt/EquityHealth
2.841/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : ASTH

The strongest argument for ASTH centers on Revenue Growth, EPS Growth, Price/Book. Revenue growth of 48.5% demonstrates continued momentum.

Bull Case : THC

The strongest argument for THC centers on P/E Ratio, Return on Equity, EPS Growth.

Bear Case : ASTH

The primary concerns for ASTH are Market Cap, Return on Equity, Profit Margin. A P/E of 46.4x leaves little room for execution misses. Thin 1.1% margins leave little buffer for downturns.

Bear Case : THC

The primary concerns for THC are PEG Ratio, Altman Z-Score, Debt/Equity. Debt-to-equity of 2.84 is elevated, increasing financial risk.

Key Dynamics to Monitor

ASTH profiles as a hypergrowth stock while THC is a value play — different risk/reward profiles.

THC carries more volatility with a beta of 1.23 — expect wider price swings.

ASTH is growing revenue faster at 48.5% — sustainability is the question.

THC generates stronger free cash flow (417M), providing more financial flexibility.

Bottom Line

THC scores higher overall (74/100 vs 56/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Astrana Health Inc

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Astrana Health, Inc., Inc., a physician-centric technology-powered healthcare management company, provides medical care services in the United States. The company is headquartered in Alhambra, California.

Tenet Healthcare Corporation

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Tenet Healthcare Corporation is a diversified health services company. The company is headquartered in Dallas, Texas.

Want to dig deeper into these stocks?